Filled buprenorphine prescriptions for opioid use disorder during COVID-19 pandemic

What The Study Did:

The COVID-19 pandemic has disrupted health care delivery in the United State, and researchers in this study examined changes in total U.S. retail pharmacy sales and sales of buprenorphine products with a U.S. Food and Drug Administration-approved indication for treatment of opioid use disorder.

Authors:

Thuy D. Nguyen, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.

To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamainternmed.2020.7497)

Editor’s Note:

The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory:

The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamainternalmedicine/

fullarticle/

10.

1001/

jamainternmed.

2020.

7497?guestAccessKey=

ef436ecf-e2b4-4df0-adfe-d8a288640c59&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

122120